Review Article
Positive and Negative Regulation of Ferroptosis and Its Role in Maintaining Metabolic and Redox Homeostasis

Ankita Sharma¹ and Swaran Jeet Singh Flora²

¹Department of Biotechnology, National Institute of Pharmaceutical Education and Research-Raebareli, Bijnor-Sisendi Road, Post Office Mati, Lucknow 226002, India
²Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research-Raebareli, Bijnor-Sisendi Road, Post Office Mati, Lucknow 226002, India

Correspondence should be addressed to Swaran Jeet Singh Flora; sjsflora@hotmail.com

Received 17 July 2020; Revised 31 March 2021; Accepted 16 April 2021; Published 29 April 2021

Copyright © 2021 Ankita Sharma and Swaran Jeet Singh Flora. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ferroptosis is a recently recognized regulated form of cell death characterized by accumulation of lipid-based reactive oxygen species (ROS), particularly lipid hydroperoxides and loss of activity of the lipid repair enzyme glutathione peroxidase 4 (GPX4). This iron-dependent form of cell death is morphologically, biochemically, and also genetically discrete from other regulated cell death processes, which include autophagy, apoptosis, necrosis, and necroptosis. Ferroptosis is defined by three hallmarks, defined as the loss of lipid peroxide repair capacity by GPX4, the bioavailability of redox-active iron, and oxidation of polyunsaturated fatty acid- (PUFA-) containing phospholipids. Experimentally, it can be induced by many compounds (e.g., erastin, Ras-selective lethal small-molecule 3, and buthionine sulfoximine) and also can be pharmacologically inhibited by iron chelators (e.g., deferoxamine and deferoxamine mesylate) and lipid peroxidation inhibitors (e.g., ferrostatin and liproxstatin). The sensitivity of a cell towards ferroptotic cell death is tightly associated with the metabolism of amino acid, iron, and polyunsaturated fatty acid metabolism, and also with the biosynthesis of glutathione, phospholipids, NADPH, and coenzyme Q10. Ferroptosis sensitivity is also governed by many regulatory proteins, which also link ferroptosis to the function of key tumour suppressor pathways. In this review, we highlight the discovery of ferroptosis, the mechanism of ferroptosis regulation, and its association with other cellular metabolic processes.

1. Introduction

Cell death is an indispensable biological process that critically governs the development of multicellular organisms. It needs to be balanced with cell proliferation in order to maintain tissue homeostasis and also to prevent the onset of neoplastic diseases. Cell death is a catastrophic phenomenon which could be random and/or orchestrated. However, the type of cell death induced by different intracellular disorders or environmental stresses displays miscellaneous biochemical and morphological characteristics, which forms the basis of categorizing the distinguished types of cell death. The Nomenclature Committee on Cell Death (NCCD) has classified the process of cell death into two categories: accidental or regulated [1]. Cells experiencing extreme physical, chemical, or mechanical insults undergo the accidental cell death processes which could not be regulated by molecularly targeted interventions, such accidental cell death cannot be modulated. On the contrary, the regulated cell death processes are effectively controlled by pharmacological and biochemical interventions which could be modulated by molecular mechanisms. The cells which undergo the inflammatory path of cell death follow the necrotic cell death. The removal of damaged and unnecessary cells by an organized manner is termed as apoptosis. For several years, the only therapeutically tractable mechanism of regulated cell death was thought to be apoptosis [2]. However, the role of one of several regulated nonapoptotic cell death pathways, such as autophagy, necroptosis, pyroptosis, and ferroptosis, has also begun to emerge [1]. To reestablish the loss in homeostatic
equilibrium, the exact identification of a specific cell death type is decisive. This review highlights the nonapoptotic cell death process of ferroptosis in greater details. Here, we discuss the hallmarks of ferroptosis, and its regulation by various biochemical and molecular players.

The term “ferroptosis” was coined by the lab of Dr. Brent R Stockwell in 2012 which describes a regulated cell death process which differs morphologically, biochemically, and genetically from the other forms of cell death processes: apoptosis, autophagy, and necrosis. Ferroptosis is a nonapoptotic, peroxidation-driven form of regulated cell death process identified more recently using a pharmacological approach which is characterized by the elevation of intracellular iron and oxidative stress generation in response to different stress stimuli [3]. The onset process of ferroptosis involves the iron-dependent enzymatic reaction-mediated generation of lipid soluble ROS. The detailed mechanisms of ferroptosis have extensively been studied in neurons, in glutamate-induced neurotoxicity, in organotypic hippocampal slice cultures, and in death signalling pathways induced by cerebral ischémia [4]. Iron chelators, inhibitors of lipid peroxidation, depletion of polyunsaturated fatty acids, and lipophilic antioxidants are found to work as effective suppressors of ferroptosis which have a direct correlation with the accumulation of lipid peroxidation markers.

2. Early History: Studies Linking Thiol Metabolism to Oxidative Cell Death

The history of identifying cell death with ferroptotic characteristics has been observed at various instances over the years before the detailed molecular understanding of this cell death process. Studies in the 1950s identified the essential role of extracellular cysteine and cystine for growth and proliferation of HeLa and other cells in culture [5]. The cell with cystine deficiency showed a distinct microscopic morphology which was similar to death caused by viral infection [6]. However, α-tocopherol, a lipophilic antioxidant, has shown to prevent the cell death induced in human fibroblasts cultured cells grown in cystine-free medium which led to reduction in cellular glutathione [7]. In the biochemical terms, ferroptosis is a process of lethal lipid peroxidation which involves oxidative addition of molecular oxygen (O₂) to lipids. In 1955, the first few descriptions of such enzymatic reactions were shown by Mason et al. [8] and Hayashi et al. [9] independently. In 1965, two separate groups suggested lipid peroxidation as a prime cause of cellular damage while studying drug Toxicology in the liver of CCl₄-treated rats [10, 11]. However, it was confirmed by 1980 that lipid peroxidation leads to the destruction of unsaturated lipid moieties of cell membranes, lipoproteins, and other structures leading to oxidative damage. The isolation of membrane-associated “phospholipid hydroperoxide glutathione peroxidase 4” (PHGPX or GPX4) which is the known second selenoperoxidase, after cytosolic glutathione peroxidase (GPX1) was a very significant discovery [12, 13]. In 1990s, glutathione peroxidase, was shown to protect against peroxidative damage of biological membranes and phosphatidylcholine-containing liposomes which has now been identified as the enzymatic inhibition of ferroptosis [14–17]. The importance of GPX4 in according protection against cell lethality was established by many studies in transgenic and knockout mouse models of glutathione-dependent peroxidases [18–20, 21]. Seiler et al. in 2008 explained the role of 12/15-lipoxygenase (12/15-LOX), a polyunsaturated fatty acid metabolizing enzyme, in the execution of GPX4-knockout-mediated cell death which was the breakthrough in understanding of the unique properties of GPX4-downregulation-induced cell death [22].

This provided evidence of involvement of LOX in many fatal pathologic situations [23–26] and had laid the path to understand the mechanistic explanation of “oxidative stress-induced apoptosis,” independent of activation of Bcl-2 family proteins [27, 28]. This highlighted the need to identify a unique cell death mechanism which could link membrane oxidative stress, lipid peroxidation, arachidonic acid metabolism, and glutathione peroxidase activity (or lipophilic antioxidants; vitamin E).

Reduced glutathione (γ-L-glutamyl-L-cysteinylglycine (GSH)) is an essential intracellular antioxidant synthesized from glutamate, cysteine, and glycine. This is a two-step process involving ATP-dependent cystolic enzymes glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS). Glutathione synthesis rate is largely dependent on cysteine availability. Cystine deficiency was shown to induce the serum-dependent cell death pathway, and the serum component critical for cell death was transferrin, an iron carrier. Early in the 1960s, iron was shown to contribute to lipid peroxidation-associated pathological changes in rats that could be prevented by vitamin E (tocopherols and tocotrienols), [29]. However, the addition of iron chelators, such as deferoxamine, and small molecules such as ferrostatin and liproxstatin prevents this cell death. These results established the concept that extracellular cystine and intracellular cysteine are required to maintain the biosynthesis of glutathione and to suppress a type of cell death in mammalian cells that is also preventable by treatment with iron chelators or lipophilic antioxidants. Also, the deprivation of cystine was found to be equivalent to system xc⁻ inhibition. These findings provided the evidence for a unique form of regulated cell death mechanism induced by amino acid starvation in the presence of an exogenous iron source is ferroptosis (Figure 1).

3. Ferroptosis Hallmark Triad

Studies over the past decade have defined a core ferroptotic pathway that features the requirement for iron and the accumulation of reactive oxygen species (ROS). Both iron chelators and lipophilic antioxidants potently inhibit lipid ROS accumulation and cell death in response to ferroptosis inhibitors (erastin, RSL3, and other compounds). There are three core hallmarks to differentiate ferroptotic cell death from other forms of cell death mechanisms [30].

3.1. Oxidation of Phospholipids Containing Polyunsaturated Fatty Acid. Glycerophospholipids are the main components of the cell membranes of mammalian cells which are acylated
with at least one polyunsaturated fatty acid (PUFA) chain. The phospholipid can be of thousands of types depending on chain lengths (C18 or higher), degrees of unsaturation (e.g., C18:3, C20:4, and C22:5), and also different head groups (e.g., phosphatidylethanolamine (PE), phosphatidylcholine, or phosphatidylinositol) in PUFA [31]. The deletion of LPCAT3 and ACSL4 genes which activate or incorporate the activated PUFAs into membrane PLs leads to the inhibition of ferroptosis [32–34]. Therefore, the inability of free PUFAs to promote ferroptosis is established which needs to be first activated and incorporated into membrane PLs to regulate ferroptosis [35]. Unlike saturated fatty acids and monounsaturated fatty acids, the bis-allylic hydrogen atoms present within PUFAs are highly susceptible to free radical (Gaschler & Stockwell 2017). PUFA oxidation is essential for ferroptosis in response to various stimuli like ROS and also enzyme-mediated oxidation [36, 37]. The oxidation of arachidonyl (C20:4) or adrenoyl (C22:4) fatty acyl chains in the context of PE-PLs (i.e., PUFA-PE) is specifically linked to the execution of ferroptosis [38]. However, the molecular mechanism of cell death by oxidation of membrane PUFA-PEs and other species is not clear, but it is proposed that it could be by the formation of a structured lipid pore by membrane thinning and aberrant membrane curvature, as in the cases of necroptosis and pyroptosis [38, 39]. This signifies the availability of PUFA-PLs at a sufficient concentration as the first hallmark of ferroptosis. Lipid peroxidation preferentially oxidizes polyunsaturated fatty acids (PUFAs) which include linoleic, arachidonic, and docosahexaenoic acids. The PUFAs containing a (1Z, 4Z) pentadiene moiety are highly susceptible to peroxidation. The removal of hydrogen atom from methylene carbon is the first step of oxidation that bridges the two double bonds. As a result of resonance-stabilized pi system, the lipid isomerized into a more thermodynamically stable isomer (1Z, 3E) and conjugated diene which reacts with molecular oxygen to form a lipid peroxide [40].

### Figure 1: Modulation of ferroptosis by various chemical reagents.

Ferroptosis is activated by four classes of ferroptosis inducers: (1) system xc– inhibitors, (2) GPX4 inhibitors, (3) FIN56, and (4) FNO2. Apart from these canonical ferroptosis inducers, many other reagents can also induce ferroptosis like buthionine sulfoximine (BSO) and ferric ammonium citrate. Ferroptosis is also inhibited by several pharmacological and genetic agents which inhibit lipid metabolism, lipid peroxidation, and iron metabolism. Vitamin E family (tocopherols and tocotrienols), small molecules, and flavonoids can inhibit LOX activity. Dopamine which is a neurotransmitter also leads to cell survival by blocking GPX4 degradation.
containing lipoxygenase enzymes to oxidize membrane PUFAs, leading to the formation of lipid ROS. Free intracellular iron and the presence of membrane PL-PUFAs are critically required the initiation and execution of ferroptosis. Iron chelators (deferoxamine and ciclopiox) interfere with the generation of oxidized lipid species which thus inhibits ferroptosis [41]. Iron is imported into the cell as iron-transferrin complexes where the internalized transferrin receptor/transferrin-iron complexes localize to the lysosome [42]. Downregulation of cytosolic import of transferrin-iron complexes suppresses ferroptosis, because of decrease in cellular iron concentration [43, 44]. The acidic pH of the lysosome causes the release of iron from iron-transferrin complexes to the cytosol. In cytosol, ferritin nanocages are the major storehouses of iron, which gets released via NCOA4-dependent ferritinophagy [45]. CDGSH iron-sulfur domain 1 and the cysteine desulfurase NFS1 are the proteins responsible for utilization of iron for iron-sulfur cluster biogenesis. They tend to reduce the sensitivity of ferroptosis by preventing the accumulation of free, redox-active iron [46]. Therefore, the second hallmark of ferroptosis sensitivity is the presence of redox-active iron.

3.3. Loss of Lipid Peroxide Repair. The iron-catalysed PL-PUFA oxidation is a highly regulated process because of its potential toxic nature. Glutathione- (GSH-) dependent lipid hydroperoxidase specifically catalyses the reduction of lipid hydroperoxides to lipid alcohols in cell membranes [47]. GPX4 is an antioxidant enzyme preventing the accumulation of toxic lipid ROS during ferroptosis. GPX4 inactivation leads to the induction of ferroptosis in many cell types, whereas in mice, the deletion of this gene is found to cause lethality [48, 49]. Other small-molecule lipophilic antioxidants, like coenzyme Q10 (CoQ10) and vitamin E (α-tocopherol), also detoxify membrane lipid ROS. Unlike the endogenous antioxidants, several exogenous lipophilic antioxidants (e.g., ferrostatin-1 and liproxstatin-1) [3, 50] also inhibit ferroptosis by preventing the propagation of oxidative damage within the membrane [51]. Thus, the loss of the repair system for eliminating lipid hydroperoxides from PUFA-PLs compromises the third hallmark of ferroptosis.

4. Biochemical Regulation of Ferroptosis
The initiation and execution of ferroptosis is a highly regulated process which lies at the junction of lipid, amino acid, and iron metabolism (Figure 2).

4.1. Prerequisite of Amino Acid and Glutathione Metabolism in Ferroptosis Regulation. Since the biosynthesis of glutathione one depends upon cysteine availability, therefore, metabolism of amino acid is intricately linked to ferroptosis regulation [52]. The cysteine is made available by the cystolic import via the cystine/glutamate antiporter system xc−; however, some cells also utilize transsulfuration pathway to biosynthesize cysteine from methionine. This bypasses the requirement for cysteine making them resistant to ferroptosis induced by system xc− inhibitors. Glutamate and glutamine are also important regulatory roles in ferroptosis [53]. System xc− exchanges glutamate for cysteine in a 1:1 ratio which thus impacts system xc− function. Higher concentrations of glutamate cause neurotoxicity since high extracellular concentrations of glutamate induce ferroptosis by inhibiting system xc− [3]. Thus, accumulation of extracellular glutamate serves to trigger the induction of ferroptosis in physiological contexts. Also, glutamine is present in human tissues and plasma at a higher concentration. The degradation of glutamine via glutaminolysis provides fuel for tricarboxylic acid (TCA) cycle and building blocks for other essential biosynthetic processes, like lipid biosynthesis. Also, α-ketoglutarate (αKG), a product of glutaminolysis, is required for ferroptosis [53]. Therefore, cellular conditions are when glutamine is absent, glutaminolysis is inhibited, or the depletion of cysteine and/or blockage of cystine import does not lead to the accumulation of ROS, lipid peroxidation, and ferroptosis. However, not all the routes of glutaminolysis are needed for ferroptosis induction. GLS1 and GLS2 are the two glutaminases that catalyse the first step of glutaminolysis which is the conversion of glutamine into glutamate. Both these glutaminase are structurally and enzymatically similar, but still only GLS2 is required for ferroptosis which is also the transcriptional target of the tumour suppressor p53 [53, 54].

4.2. Intricate Association between Ferroptosis and Lipid Metabolism. Ferroptotic cell death is very intricately associated with the cellular lipid metabolism. As discussed earlier, PUFAs are highly susceptible to lipid peroxidation which is a prerequisite for the execution of ferroptosis. The availability and spatial localization of PUFAs determine the extent of cellular lipid peroxidation which has a direct relation with the execution of ferroptosis. Nonheme, iron-containing proteins, which includes lipoxygenases (LOXs), also act as enzymatic effectors mediating the ferroptotic peroxidation [22, 35, 37]. LOXs preferably catalyse the peroxidation of free PUFAs, rather than PUFAs-containing phospholipids [35]. For this, PE phospholipids form a nonbilayer arrangement facilitating the proferroptotic oxidation of polyunsaturated fatty acid-containing PE phospholipids [56]. Genetic depletion of LOXs protects against erastin-induced ferroptosis, highlighting the contribution of LOXs in ferroptosis. Some lipoxygenases are also required for normal embryonic development in vertebrates. 12S-Lipoxygenase is indispensable for the development of numerous tissues in zebrafish which suggests that ferroptosis could also be involved in several developmental processes [57], since lipid peroxidation is the ultimate requirement for the execution of ferroptosis. Aldehydes and Michael acceptors are the reactive derivatives of lipid peroxides which react with nucleic acids and proteins [40]. The cell line selected for erastin resistance showed upregulation of aldo-keto reductase-encoding genes, AKR1C, which reduce lipid peroxidation reactive end-products to unreactive compounds [58].

4.3. Effects of Bioavailability of Iron on Ferroptosis. As the name suggests, iron is essential for ferroptotic cell death for the accumulation of lipid peroxides. The sensitivity of a cell towards ferroptosis depends on iron import, export, storage, and turnover. Transferrin and transferrin receptors, which
are required for the iron import, are required for ferroptosis [4]. IREB2, the iron metabolism master regulator upon inhibition, decreases sensitivity to ferroptosis [3]. Since the iron metabolism is also impacted by autophagy, it also regulates ferroptosis in many ways [59]. Ferritinophagy is the selective autophagy of ferritin in which the ferritin is recognized by the specific cargo receptor NCOA4, which directs it to autophagosomes for lysosomal degradation. This lysosomal degradation of ferritin releases the free iron thus increasing the ferroptosis sensitivity [45]. Apart from ferritin, HSPB1 and CISD1 are other protein affecting the ferroptosis sensitivity. Thus, the regulation of ferroptosis by modulating iron metabolism and ferritinophagy is also of greater concern.

5. Molecular Regulation of Ferroptosis

Ferroptosis is characterized by the interplay of iron accumulation, excessive ROS levels, and lipid peroxidation where lipid hydroperoxide detoxification pathway activity is decreased. The biochemical mechanisms linking oxidative stress to mitochondrial dysfunction in ferroptosis have been elucidated and identified [60]. Therefore, genes and pathways that regulate iron homeostasis, endogenous lipophilic antioxidant pathways, PUFA metabolism, GPX4 expression, or GPX4 activity have emerged as imperative regulators of ferroptosis, since dysregulation of ferroptosis is also associated with many pathological conditions, because of its association with other biological processes such as immune

Figure 2: Regulation of ferroptosis by amino acid, lipid, and iron metabolism. The initiation and execution of ferroptosis are regulated by the metabolism of amino acid, lipid, and iron. The three hallmarks of ferroptosis are the presence of polyunsaturated fatty acid- (PUFA-) acylated phospholipids (PLs), redox-active iron, and loss in lipid peroxide repair. System xc− imports cystine, which gets reduced to cysteine to synthesize glutathione. GPX4 carries out the elimination of lipid peroxides by utilizing glutathione as a necessary cofactor. Transferrin and transferrin receptors are required for ferroptosis which import iron from the extracellular environment. Iron is essentially required for the accumulation of lipid peroxides. Stored Fe(III) in ferritin is retrieved by autophagy, and also, heme can be degraded by heme oxygenases (HOs) to recover Fe(II).
responses [61], autophagy [62], and metabolism [63]. Therefore, few of the regulators of these biological processes which also affect the sensitivity of ferroptosis are explained in the following section (Figure 3).

5.1. Nrf2 Regulates All the Physiological Aspects of Ferroptosis.

The nuclear factor erythroid 2-related factor 2 (Nrf2) is a key regulatory protein of the antioxidant response against the cellular oxidant imbalance [64]. Under normal physiological conditions, cellular Nrf2 is maintained in low amounts by its inhibitory protein, Kelch-like ECH-associated protein 1-(Keap1-) mediated proteasomal degradation. Under oxidative stress conditions, Nrf2 protein is stabilized and initiates a multistep pathway of activation that includes nuclear localization, heterodimerization with its partner small v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog (MaF) proteins such as MaFG, recruitment of transcriptional coactivators, and subsequent binding to antioxidant response elements (ARE) of target antioxidant genes.

Nrf2 activation has been greatly linked to protection against cell death, but its role in the regulation of ferroptotic cell death and its relationship with iron signalling are the recently explored area. Nrf2 is found to transcriptionally regulate almost all genes implicated in ferroptosis which include NADPH regeneration which is critical for Gpx4 activity (phosphoglucurate dehydrogenase, malic enzyme, and glucose 6-phosphate dehydrogenase) and genes for glutathione regulation (synthesis, cysteine supply via system xc−, glutathione peroxidase 4, and glutathione reductase) [65]. Nrf2 can also regulate the iron metabolism genes and attenuate ferroptosis through preventing free iron availability. The light chain and heavy chain of ferritin (FTL/FTH1), which is a key iron storage protein, and also ferroportin (SLC40A1), which regulates the efflux out of iron from the cell, are also regulated by Nrf2 [66, 67]. The Nrf2 is the vital inhibitor of ferroptosis due to its ability to inhibit cellular iron uptake, limiting ROS production and upregulating SLC7A11, which are indispensable for GSH synthesis [68].

Nrf2 also reciprocally regulates the metabolism of lipids mediated via ligand-mediated transcription factor peroxisome proliferator-activated receptor gamma (PPARγ) [69, 70]. The relevance of PPARγ in the regulation of ferroptosis is evident since it gets activated by oxidized lipids which are also relevant to the initiation of ferroptosis [71]. Hence, the regulation of ferroptosis by Nrf2 is indirect by modulating the lipids whose abundance contributes to the sensitivity to ferroptosis [32].

Nrf2 has recently been found to prevent the ferroptotic cell death by implying various direct mechanisms. Nrf2 regulates cellular iron and ROS metabolism via p62-Keap1-NRF2 pathway where it protects hepatocellular carcinoma cells against ferroptosis through upregulation of multiple genes (heme oxygenase-1 (HO1) and quinone oxidoreductase-1 (NQO1)). However, the knockdown of NQO1, HO1, and FTH1 followed by ferroptotic inducers increased the growth inhibition in HCC cells showing the negative modulatory activities of Nrf2 ferroptosis by its targeted genes [72]. Also, GPX4 which is a GSH-linked active ROS antagonist enzyme is one of the important targets of Nrf2 as mentioned above [73]. Moreover, inhibition of Nrf2 expression and activity in vitro and in vivo increased the anticancerous activity of erastin and sorafenib in HCC cells which are ferroptosis inhibitors [72, 74].

Ultimately, ROS is the indispensable molecule in the ferroptotic cell death. Previous studies have confirmed that miRNAs are intimately related to redox signalling and ROS production, which can therefore also regulate ferroptosis by regulating the expression of ROS. Nrf2 pathway is also readily activated by miR-7 and miR-200a which mediate the repression of Keap1 expression [75, 76]. On the contrary, the expression of Nrf2 is suppressed by miR-28 in a Keap1-independent way [77]. miR-101 and miR-455 target Cullin-3 (Cul3) to promote the nuclear accumulation of Nrf2 [78, 79]. Finally, miR-93 [80], miR-144 [81], miR-153, miR-142-5p, miR-27a [82], miR-193b, miR-29-b1 [83], miR-365-1, and miR-34a [84] also downregulate Nrf2 level through various mechanisms. This postulates the hypothesis that miRNA might modify ferroptosis by means of regulating the expression of Nrf2.

5.2. Beclin-1 Is a New Regulator of Ferroptosis. Beclin-1 (Vps30/Atg6 in yeast) is a recognized autophagy regulator that is involved in the generation of the PtdIns3K complex which is essentially involved in activating autophagy [85]. Beclin-1 also is a critical regulator of ferroptosis, which is independent of the formation of the PtdIns3K complex. Beclin-1 expression only affects system xc− inhibitor-induced ferroptosis. Knockdown of Beclin-1 by RNA interference (RNAi) blocks ferroptosis, whereas knocking of Beclin-1 by gene transfection promotes ferroptosis in cancer cells in response to system xc− inhibitors (e.g., erastin, sulfasalazine, and sorafenib). In contrast, suppression of a paralog of BECN1, Becn2 expression, does not affect erastin-, sorafenib-, or sulfasalazine-induced ferroptosis. This suggests that only Beclin-1 and not Beclin-2 is obligatory for system xc− inhibitor-induced ferroptosis [86].

Ferroptosis needs ATG5 (autophagy related 5) and NCOA4 (nuclear receptor coactivator 4). ATG5 is a part of an E3-like ligase which is critical for the lipidation of members of the GABARAP (GABA type-A receptor-associated protein families) and MAP1LC3 (microtubule-associated protein 1 light chain 3). However, NCOA4 is a cargo receptor which mediates FT/ferritin degradation via selective ferritophagy. Suppression of Atg5 by knockdown inhibits erastin-induced conversion of MAP1LC3B-I to MAP1LC3B-II. Also, suppression of NCOA4 blocks FT/ferritin degradation which results in suppression of ferroptosis. On the contrary, either knockdown or knocking of Beclin-1 does not affect the synthesis of lipaplated MAP1LC3B and MAP1LC3B-positive puncta in ferroptosis. As a positive control in starvation-induced cells, knockdown of Beclin-1 stops conversion of MAP1LC3B-I to MAP1LC3B-II. Significantly, the formation of a BECN1-PtdIns3K complex was only observed in cancer cells in response to starvation, but not against ferroptotic stimulus. These findings point to the regulatory roles of Beclin-1 in ferroptosis as compared to starvation-induced autophagy [87].
Figure 3: A schematic model describing the roles of various stress signalling pathways in the regulation of ferroptosis; p53 exhibits a dual regulatory roles in the control of ferroptosis. p53 increases ferroptosis either by inhibiting SLC7A11 expression or by activating SAT1 and GLS2 expression. p53-mediated inhibition of ferroptosis is mediated either by inhibiting DPP4 activity or inducing Cdkn1a/p21 expression. ATM-mediated resistance to ferroptosis is induced by ATM inactivation. Upon ATM inactivation, the nuclear import of MTF1 protein is increased which transcriptionally activates the expression of ferroportin (FPN1) and ferritin (FTH1 and FTL) which leads to the presence of low-labile iron in the cell. Activation of the p62-Kap1- (Kelch-like ECH-associated protein 1-) Nrf2 (nuclear factor erythroid 2-related factor 2) pathway also regulates ferroptosis. Nrf2 plays the central regulatory role in the regulation of metabolism autophagy, or mTORC1 signalling. BECN1 promotes ferroptosis by binding to SLC7A11 and thus blocking the system xc− activity.

The biochemical events which lead to ferroptosis majorly include lipid peroxidation and iron accumulation. However, the Beclin-1-mediated regulation of ferroptosis does not affect either intracellular iron accumulation or iron metabolism-associated expression. On the contrary, Beclin-1 promotes lipid peroxidation in the process of regulating ferroptosis. These findings suggest that BECN1 promotes ferroptosis also through regulation of lipid peroxidation [88].

5.3. Regulation of Ferroptosis by AMPK Is Context Dependent. AMP-activated protein kinase (AMPK), a critical sensor of cellular energy status, gets activated via AMP binding, upstream kinase phosphorylation, and other mechanisms. AMPK restores the energy balance and maintains cell survival under conditions of energy stress [89]. Since the unresolved energy stress has found to eventually induce apoptosis, the mechanism by which other nonapoptotic forms of regulated cell death are regulated is largely unknown. There are accumulating evidences which indicate an intimate relationship between metabolism and ferroptosis [41, 90].

Several in vitro studies have shown that the inactivation of AMPK greatly abolishes the protective effects of energy stress on ferroptosis. Also, the in vivo studies reveal the inhibition of ferroptosis-associated renal ischaemia-reperfusion injury upon AMPK inactivation. Cancer cells are shown to exhibit resistance to ferroptosis since they have a higher basal AMPK activation. However, these cells were found to be sensitized towards ferroptosis once there was physiological inhibition of AMPK activation, since AMPK also exhibits various regulatory roles in the lipid metabolism by mediating the phosphorylation of acetyl-CoA carboxylase and also polyunsaturated fatty acid biosynthesis. Importantly, loss of function of tumour suppressor liver kinase B1 (LKB1) sensitizes mouse embryonic fibroblasts (MEFs) and human non-small cell lung carcinoma cell lines to ferroptosis. This highlights the vital role of LKB1-AMPK-ACC1-FAS axis in regulating ferroptotic cell death [91]. Therefore, the functional and lipidosome analysis further links AMPK regulation to ferroptosis. Recently, a study has shown that mitochondria play an integral role in regulating ferroptosis [92]. AMPK activation is also found to regulate the mitochondrial homeostasis [93]. However, there are strikingly different functions between mitochondria and AMPK in ferroptosis, wherein mitochondria selectively promote erastin-induced or cystine-starvation-induced, but not RSL3-induced, ferroptosis [92], while energy stress-mediated AMPK activation inhibits ferroptosis through mitochondria-independent mechanisms [94]. The inhibitory effect of AMPK activation on ferroptosis does not involve the modulation of cystine uptake, iron metabolism autophagy, or mTORC1 signalling.
A recent study also reported a promoting role of AMPK in the regulation of ferroptosis mediated by Beclin-1. Beclin-1 is a key player of macroautophagic/autophagy, but at a few instances, it also plays a nonautophagic role in promoting ferroptosis by binding to SLC7A11. Notably, AMPK mediates the phosphorylation of Beclin-1 at Ser90/93/96. This is the prerequisite for the formation of Beclin1-SLC7A11 complex and subsequent lipid peroxidation in ferroptosis. Inhibition of AMPK by siRNA or compound C diminishes erastin-induced Beclin-1 phosphorylation at S93/96, which thus inhibits the formation of Beclin-1-SLC7A11 complex formation, and subsequent ferroptosis. Thus, it is evident that Beclin-1 contributes to the core molecular machinery and signalling pathways involved in ferroptosis [86]. It is possible that AMPK-mediated regulatory mechanisms of ferroptosis are context dependent and thus await for further investigation in future studies.

5.4. The Bifunctional Nature of Relationship between Tumour Suppressor Protein, p53, and Ferroptosis Network. Tumour suppressor protein p53 (TP53) plays a critical role in the cellular response to various stresses, including hypoxia, nutrition starvation, DNA damage, and oncogene activation [95]. p53 plays a dual role depending upon the stress conditions; it can either lead to cell survival or cell death including apoptosis and autophagy [96]. p53 has also been found to regulate ferroptosis at either transcriptional or posttranslational levels. p53 is found to exhibit both the properties; on one hand, it has prodeath function in ferroptosis, and on the other hand, it also shows prosurvival properties in ferroptosis [97]. p53-induced ferroptotic cell death is mediated by the inhibition of SLC7A11 expression, promotion of SAT1 expression, and promotion of GLS2 expression [98]. The transrepression of SLC7A11 expression by p53 activation is found to promote ferroptosis in fibroblasts and other cancer cells (human osteosarcoma U2OS and human breast cancer MCF7). For instance, p533KR, an acetylation-defective mutant with 3 lysine residues (in positions 117, 161, and 162) getting replaced by arginine residues, is found to be defective in repressing SLC7A11 at Ser90/93/96. This is the prerequisite for the formation of Beclin1-SLC7A11 complex and subsequent lipid peroxidation in ferroptosis. Inhibition of AMPK by siRNA or compound C diminishes erastin-induced Beclin-1 phosphorylation at S93/96, which thus inhibits the formation of Beclin1-SLC7A11 complex formation, and subsequent ferroptosis. Thus, it is evident that Beclin-1 contributes to the core molecular machinery and signalling pathways involved in ferroptosis [86]. It is possible that AMPK-mediated regulatory mechanisms of ferroptosis are context dependent and thus await for further investigation in future studies.

Inhibition of p53 by either by knockdown or by pharmacological inhibition of ALOX15 by PD146176 which diminishes erastin-induced Beclin-1 phosphorylation at S93/96, which thus inhibits the formation of Beclin1-SLC7A11 complex formation, and subsequent ferroptosis. Inhibition of AMPK by siRNA or compound C diminishes erastin-induced Beclin-1 phosphorylation at S93/96, which thus inhibits the formation of Beclin1-SLC7A11 complex formation, and subsequent ferroptosis. Thus, it is evident that Beclin-1 contributes to the core molecular machinery and signalling pathways involved in ferroptosis [86]. It is possible that AMPK-mediated regulatory mechanisms of ferroptosis are context dependent and thus await for further investigation in future studies.
5.5. Signalling Downstream of Ataxia-Telangiectasia-Mutated Kinase in Ferroptosis Regulation. Ataxia-telangiectasia-mutated kinase (ATM) is a kinase crucial for the DNA damage responses [109]. p53 is one of its downstream targets which plays a very decisive role in regulating ferroptosis which prompts its role in the ferroptosis [110]. Inhibition of ATM either by genetic knockdown or by pharmacologically suppressing ferroptotic cell death also decreases intracellular labile iron via increasing iron export (increased FPN1) and sequestration (increased FTH1 and FTL). This synchronized change in the iron regulators during ATM inhibition results in the depletion of labile iron pool which thus prevents the iron-dependent ferroptosis. These coordinated changes rely greatly on transcriptional activity and nuclear translocation of metal-regulatory transcription factor 1 (MTF1) upon ATM inhibition. Under the conditions of ATM inhibition, the nuclear translocation of MTF1 is increased which leads to inhibition of ferroptosis by the alterations in the expression of ferritin (FTH1) and ferroportin (FPN1). In conditions where activity of MTF-1 is depleted, the cells show a greater sensitivity to ferroptosis signifying the prevalence of ATM-MTF1-ferritin/FPN1 regulatory axis regulating labile iron levels [111].

6. Conclusion and Future Direction

Ferroptosis as the name suggests is a unique regulated form of the cell death pathway associated with iron overload, with many of its physiological roles yet to be defined. The molecular mechanism of ferroptosis is far more complex than previously thought and is entirely different from other regulated cell death processes including apoptosis, necroptosis, and autophagy. Extensive research which deals with understanding the fine regulatory mechanisms of ferroptosis is growing with a very fast pace. However, many studies have also shown the contradictory relationship of ferroptosis with other types of cell death types. Several regulatory proteins have been identified recently which regulate ferroptosis by either direct or indirect mechanisms with many targeting iron metabolism and lipid peroxidation. Many of these ferroptosis regulators are also associated in other types of RCD. Therefore, the imperative objective in the study of ferroptosis is the identification of executors or immediate downstream signalling pathways which might distinguish ferroptosis from other types of RCD. This will elucidate the further molecular controls of this process and also explain its involvement in various diseases, and its physiological and evolutionary functions.

Abbreviations

| Abbreviation | Description                                      |
|--------------|--------------------------------------------------|
| 12/15-LOX    | 12/15-Lipoxygenase                               |
| 15-LOX       | 15-Lipoxygenase                                  |
| AA           | Arachidonic acid                                 |
| ACC          | Acetyl-CoA carboxylase                           |
| ACSL4        | Acyl-CoA synthetase long chain family member 4   |
| AKR1C        | Aldo-keto reductases                             |
| AMPK         | AMP-activated protein kinase                      |
| ARE          | Antioxidant response elements                    |
| ATG          | Autophagy related gene                           |
| ATM          | Ataxia-telangiectasia-mutated kinase             |
| CDKN1A/p21   | Cyclin-dependent kinase inhibitor 1A             |
| CoQ10        | Coenzyme Q10                                     |
| Cul3         | Cullin-3                                         |
| DPP4         | Dipeptidyl peptidase-4                          |
| FPN1         | Ferroportin                                      |
| FTH1         | Ferritin                                         |
| GABARAP      | GABA type-A receptor-associated protein          |
| GCL          | Glutamate-cysteine ligase                        |
| GLS          | Glutaminases                                     |
| GPX          | Glutathione peroxidase                           |
| GSH          | γ-L-Glutamyl-L-cysteinylglycine                   |
| GSS          | Glutathione synthetase                           |
| HO1          | Heme oxygenase-1                                 |
| Keap1        | Kelch-like ECH-associated protein 1              |
| LPCAT3       | Lysophosphatidylcholine acyltransferase 3       |
| Maf          | Musculoaponeurotic fibrosarcoma                  |
| MAP1LC3      | Microtubule-associated protein 1 light chain 3   |
| MTF1         | Metal-regulatory transcription factor 1          |
| NCCD         | Nomenclature Committee on Cell Death            |
| NCOA4        | Nuclear receptor coactivator 4                   |
| NQO1         | Quinone oxidoreductase-1                         |
| Nrf2         | Nuclear factor erythroid 2-related factor 2      |
| PE           | Phosphatidylethanolamine                         |
| PHGPX        | Phospholipid hydroperoxide glutathione peroxidase|
| PL           | Phospholipid                                     |
| PPARγ        | Peroxisome proliferator-activated receptor gamma |
| PUFA         | Polyunsaturated fatty acid                       |
| PUFA-PL      | Polyunsaturated fatty acid-containing phospholipids|
| PUFAs        | Polyunsaturated fatty acids                      |
| ROS          | Reactive oxygen species                          |
| RSL3         | Ras-selective lethal small-molecule 3            |
| SAT1         | Spermidine/Spermine N1-acetyltransferase 1      |
| SLC7A11      | Solute carrier family 7 member 11                |
| TP53         | Tumour suppressor protein p53                    |
| ATM          | Ataxia-telangiectasia-mutated kinase             |
| ARE          | Antioxidant response elements                    |
| ATG          | Autophagy related gene                           |
| ATM          | Ataxia-telangiectasia-mutated kinase             |
| CDKN1A/p21   | Cyclin-dependent kinase inhibitor 1A             |
| CoQ10        | Coenzyme Q10                                     |
| Cul3         | Cullin-3                                         |
| DPP4         | Dipeptidyl peptidase-4                          |
| FPN1         | Ferroportin                                      |
| FTH1         | Ferritin                                         |
| GABARAP      | GABA type-A receptor-associated protein          |
| GCL          | Glutamate-cysteine ligase                        |
| GLS          | Glutaminases                                     |
| GPX          | Glutathione peroxidase                           |
| GSH          | γ-L-Glutamyl-L-cysteinylglycine                   |
| GSS          | Glutathione synthetase                           |
| HO1          | Heme oxygenase-1                                 |
| Keap1        | Kelch-like ECH-associated protein 1              |
| LPCAT3       | Lysophosphatidylcholine acyltransferase 3       |
| Maf          | Musculoaponeurotic fibrosarcoma                  |
| MAP1LC3      | Microtubule-associated protein 1 light chain 3   |
| MTF1         | Metal-regulatory transcription factor 1          |
| NCCD         | Nomenclature Committee on Cell Death            |
| NCOA4        | Nuclear receptor coactivator 4                   |
| NQO1         | Quinone oxidoreductase-1                         |
| Nrf2         | Nuclear factor erythroid 2-related factor 2      |
| PE           | Phosphatidylethanolamine                         |
| PHGPX        | Phospholipid hydroperoxide glutathione peroxidase|
| PL           | Phospholipid                                     |
| PPARγ        | Peroxisome proliferator-activated receptor gamma |
| PUFA         | Polyunsaturated fatty acid                       |
| PUFA-PL      | Polyunsaturated fatty acid-containing phospholipids|
| PUFAs        | Polyunsaturated fatty acids                      |
| ROS          | Reactive oxygen species                          |
| RSL3         | Ras-selective lethal small-molecule 3            |
| SAT1         | Spermidine/Spermine N1-acetyltransferase 1      |
| SLC7A11      | Solute carrier family 7 member 11                |
| TP53         | Tumour suppressor protein p53                    |

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] L. Galluzzi, I. Vitale, S. A. Aaronson et al., “Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018,” Cell Death & Differentiation, vol. 25, no. 3, pp. 486–514, 2018.

[2] M. Conrad, J. P. F. Angeli, P. Vandenabeele, and B. R. Stockwell, "Regulated necrosis: disease relevance and therapeutic opportunities," Nature Reviews Drug Discovery, vol. 15, no. 5, pp. 348–366, 2016.

[3] S. J. Dixon, K. M. Lemberg, M. R. Lamprecht et al., “Ferroptosis: an iron-dependent form of nonapoptotic cell death,” Cell, vol. 149, no. 5, pp. 1060–1072, 2012.
[4] W. S. Yang and B. R. Stockwell, "Ferroptosis: death by lipid peroxidation," *Trends in Cell Biology*, vol. 26, no. 3, pp. 165–176, 2016.

[5] H. Eagle, "Amino acid metabolism in mammalian cell cultures," *Science*, vol. 130, no. 3373, pp. 432–437, 1959.

[6] H. Eagle, "The specific amino acid requirements of a human carcinoma cell (strain HeLa) in tissue culture," *The Journal of Experimental Medicine*, vol. 102, no. 1, pp. 37–48, 1955.

[7] S. Bannai, H. Tsukeda, and H. Okumura, " Effect of antioxidants on cultured human diploid fibroblasts exposed to cysteine-free medium," *Biochemical and Biophysical Research Communications*, vol. 74, no. 4, pp. 1582–1588, 1977.

[8] H. Mason, W. Fowlks, and E. Peterson, "Oxygen transfer and electron transport by the phenolase complex I," *Journal of the American Chemical Society*, vol. 77, no. 10, pp. 2914–2915, 1955.

[9] O. Hayashi, M. Katagiri, and S. Rothberg, "Specific peroxidase in the pyrocatechase reaction," *Journal of the American Chemical Society*, vol. 77, no. 20, pp. 5450–5451, 1955.

[10] M. Comporti, C. Saccocci, and M. Dianzani, "Effect of CCI-4 in vitro and in vivo on lipid peroxidation of rat liver homogenates and subcellular fractions," *Enzymologia*, vol. 29, no. 3, pp. 185–204, 1965.

[11] A. K. Ghoshal and R. O. Recknagel, "Positive evidence of acceleration of lipoperoxidation in rat liver by carbon tetrachloride: in vitro experiments," *Life Sciences*, vol. 4, no. 15, pp. 1521–1530, 1965.

[12] L. Flohé, W. Gunzler, and H. Schock, "FEBS Lett 32: 132; (b) Rottrup JT, Pope AL, Ganther HE, Swanson AB, Haifeman DG, Hoeckstra WG (1973), Science, vol. 179, p. 588, 1973.

[13] G. C. Mills, "Hemoglobin catabolism I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown," *Journal of Biological Chemistry*, vol. 229, no. 1, pp. 189–197, 1957.

[14] J. P. Thomas, P. G. Geiger, M. Maiorino, F. Ursini, and A. W. Girotti, "Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins," *Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism*, vol. 1045, no. 3, pp. 252–260, 1990.

[15] J. Thomas, M. Maiorino, F. Ursini, and A. Girotti, "Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides," *Journal of Biological Chemistry*, vol. 265, no. 1, pp. 454–461, 1990.

[16] F. Ursini and A. Bindoli, "The role of selenium peroxidases in the protection against oxidative damage of membranes," *Chemistry and Physics of Lipids*, vol. 44, no. 2-4, pp. 255–276, 1987.

[17] L. Zhang, M. Maiorino, A. Roveri, and F. Ursini, "Phospholipid hydroperoxide glutathione peroxidase: specific activity in tissues of rats of different age and comparison with other glutathione peroxidases," *Biochimica et Biophysica Acta (BBA)-Lipids and Lipid Metabolism*, vol. 1006, no. 1, pp. 140–143, 1989.

[18] W.-H. Cheng, Y.-S. Ho, D. A. Ross, B. A. Valentine, G. F. Combs Jr., and X. G. Lei, "Cellular glutathione peroxidase knockout mice express normal levels of selenium-dependent plasma and phospholipid hydroperoxide glutathione peroxidases in various tissues," *The Journal of Nutrition*, vol. 127, no. 8, pp. 1445–1450, 1997.

[19] R. S. Esworthy, R. Aranda, M. G. Martin, J. H. Doroshow, S. W. Binder, and F.-F. Chu, "Mice with combined disruption of Gpx1 and Gpx2 genes have colitis," *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 281, no. 3, pp. G848–G855, 2001.

[20] M. R. Garry, T. J. Kavanagh, E. M. Faustman et al., "Sensitivity of mouse lung fibroblasts heterozygous for GPX4 to oxidative stress," *Free Radical Biology and Medicine*, vol. 44, no. 6, pp. 1075–1087, 2008.

[21] L. J. Yant, Q. Ran, L. Rao et al., "The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults," *Free Radical Biology and Medicine*, vol. 34, no. 4, pp. 496–502, 2003.

[22] A. Seller, M. Schneider, H. Förster et al., "Glutathione Peroxidase 4 Senses and Translates Oxidative Stress into 12/15-Lipoxygenase Dependent- and AIF-Mediated Cell Death," *Cell metabolism*, vol. 8, no. 3, pp. 237–248, 2008.

[23] G. Jin, K. Arai, Y. Murata et al., "Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia," *Stroke*, vol. 39, no. 9, pp. 2538–2543, 2008.

[24] K. van Leyen, H. Y. Kim, S.-R. Lee, G. Jin, K. Arai, and E. H. Lo, "Baicalein and 12/15-lipoxygenase in the ischemic brain," *Stroke*, vol. 37, no. 12, pp. 3014–3018, 2006.

[25] M. K. Middleton, A. M. Zukas, T. Rubinstein et al., "Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease," *The Journal of Experimental Medicine*, vol. 203, no. 11, pp. 2529–2540, 2006.

[26] P. Robins and T. Lindahl, "DNA Ligase IV from HeLa Cell Nuclei*," *Journal of Biological Chemistry*, vol. 279, no. 39, pp. 24257–24261, 1996.

[27] K. Nomura, H. Imai, T. Kounura, M. Arai, and Y. Nakagawa, "Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway," *Journal of Biological Chemistry*, vol. 274, no. 11, pp. 29294–29302, 1999.

[28] H. Jiang, J. Quilley, L. M. Reddy, P. Y.-K. Wong, and J. C. Mikkat, "Red blood cells: reservoirs of cis-and trans-epoxyeicosatrienoic acids," *Prostaglandins & other lipid mediators*, vol. 75, no. 1-4, pp. 65–78, 2005.

[29] L. Golberg, L. Martin, and A. Batchelor, "Biochemical changes in the tissues of animals injected with iron. 3. Lipid peroxidation," *Biochemical Journal*, vol. 83, no. 2, pp. 291–298, 1962.

[30] S. J. Dixon and B. R. Stockwell, "The hallmarks of ferroptosis," *Annual Review of Cancer Biology*, vol. 3, no. 1, pp. 35–54, 2019.

[31] L. Magtanong, P. Ko, and S. Dixon, "Emerging roles for lipids in non-apoptotic cell death," *Cell Death & Differentiation*, vol. 23, no. 7, pp. 1099–1109, 2016.

[32] S. Doll, B. Proneth, Y. Y. Tyurina et al., "ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition," *Nature Chemical Biology*, vol. 13, no. 1, pp. 91–98, 2017.

[33] S. J. Dixon, G. E. Winter, L. S. Musavi et al., "Human haploid cell genetics reveals roles for lipid metabolism genes in non-apoptotic cell death," *ACS Chemical Biology*, vol. 10, no. 7, pp. 1604–1609, 2015.

[34] J. Cheng, Y. Q. Fan, B. H. Liu, H. Zhou, J. M. Wang, and Q. X. Chen, "ACSL4 suppresses glioma cells proliferation via activating ferroptosis," *Oncology Reports*, vol. 43, no. 1, pp. 147–158, 2020.
V. E. Kagan, G. Mao, F. Qu et al., “Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis,” *Nature Chemical Biology*, vol. 13, no. 1, pp. 81–90, 2017.

R. Skouta, S. J. Dixon, J. Wang et al., “Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models,” *Journal of the American Chemical Society*, vol. 136, no. 12, pp. 4551–4556, 2014.

W. S. Yang, K. J. Kim, M. M. Gaschler, M. Patel, M. S. Shchepinov, and B. R. Stockwell, “Peroxidation of polyunsaturated fatty acids by lipoxigenases drives ferroptosis,” *Proceedings of the National Academy of Sciences*, vol. 113, no. 34, pp. E4966–E4975, 2016.

S. E. Wenzel, Y. Y. Tyurina, J. Zhao et al., “PEBP1 warden ferroptosis by enabling lipoxigenase generation of lipid death signals,” *Cell*, vol. 171, no. 3, pp. 628–641.e26, 2017.

E. Agmon, J. Solon, P. Bassereau, and B. R. Stockwell, “Modeling the effects of lipid peroxidation during ferroptosis on membrane properties,” *Scientific Reports*, vol. 8, no. 1, pp. 1–11, 2018.

M. M. Gaschler and B. R. Stockwell, “Lipid peroxidation in cell death,” *Biochemical and Biophysical Research Communications*, vol. 482, no. 3, pp. 419–425, 2017.

B. R. Stockwell, J. P. Friedmann Angeli, H. Bayir et al., “Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease,” *Cell*, vol. 171, no. 2, pp. 273–285, 2017.

S. V. Torti and F. M. Torti, “Iron and cancer: more ore to be mined,” *Nature Reviews Cancer*, vol. 13, no. 5, pp. 342–355, 2013.

M. Gao and X. Jiang, “To eat or not to eat—the metabolic flavor of ferroptosis,” *Current opinion in cell biology*, vol. 51, pp. 58–64, 2018.

S. Tortii, R. Shintoku, C. Kubota et al., “An essential role for functional lysosomes in ferroptosis of cancer cells,” *Biochemical Journal*, vol. 473, no. 6, pp. 769–777, 2016.

J. D. Mancias, X. Wang, S. P. Gygi, J. W. Harper, and A. C. Kimmelman, “Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferroptophagy,” *Nature*, vol. 509, no. 7498, pp. 105–109, 2014.

S. W. Alvarez, V. O. Sviderskii, E. M. Terzi et al., “NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis,” *Nature*, vol. 551, no. 7682, pp. 639–643, 2017.

F. Ursini, M. Maiorino, and C. Gregolin, “The selenoenzyme phospholipid hydroperoxide glutathione peroxidase,” *Biochimica et Biophysica Acta (BBA)-General Subjects*, vol. 839, no. 1, pp. 62–70, 1985.

W. S. Yang, R. SriRamaratnam, M. E. Welsch et al., “Regulation of ferroptotic cancer cell death by GPX4,” *Cell*, vol. 156, no. 1-2, pp. 317–331, 2016.

I. Ingold, C. Berndt, S. Schmitt et al., “Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis,” *Cell*, vol. 172, no. 3, pp. 409–422.e21, 2018.

J. P. Friedmann Angeli, M. Schneider, B. Proneth et al., “Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice,” *Nature Cell Biology*, vol. 16, no. 12, pp. 1180–1191, 2014.

O. Zilka, R. Shah, B. Li et al., “On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death,” *ACS Central Science*, vol. 3, no. 3, pp. 232–243, 2017.

J. P. F. Angeli, R. Shah, D. A. Pratt, and M. Conrad, “Ferroptosis inhibition: mechanisms and opportunities,” *Trends in Pharmacological Sciences*, vol. 38, no. 5, pp. 489–498, 2017.

M. Gao, P. Monian, N. Quadri, R. Ramasamy, and X. Jiang, “Glutaminolysis and trans ferrin regulate ferroptosis,” *Molecular Cell*, vol. 59, no. 2, pp. 298–308, 2015.

M. Jennis, C.-P. Kung, S. Basu et al., “An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model,” *Genes & Development*, vol. 30, no. 8, pp. 918–930, 2016.

H. Kuhn, S. Bantiyha, and K. Van Leyen, “Mammalian lipoxigenases and their biological relevance,” *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids*, vol. 1851, no. 4, pp. 308–330, 2015.

E. van den Brink-van der Laan, J. Antoinette Killian, and B. de Kruiff, “Nonbilayer lipids affect peripheral and integral membrane proteins via changes in the lateral pressure profile,” *Biochimica et Biophysica Acta (BBA)-Biomembranes*, vol. 1666, no. 1–2, pp. 275–288, 2004.

U. Haas, E. Raschberger, M. Hamberg, B. Samuelsson, K. Tryggvason, and J. Z. Haeggström, “Targeted knock-down of a structurally atypical zebrafish 12S-lipoxigenase leads to severe impairment of embryonic development,” *Proceedings of the National Academy of Sciences*, vol. 108, no. 51, pp. 20479–20484, 2011.

A. K. MacLeod, M. McMahon, S. M. Plummer et al., “Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1–NRF2 pathway, and not the BACH1–NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds,” *Carcinogenesis*, vol. 30, no. 9, pp. 1571–1580, 2009.

J. Liu, F. Kuang, G. Kroemer, D. J. Klionsky, R. Kang, and D. Tang, “Autophagy-dependent ferroptosis: machinery and regulation,” *Cell Chemical Biology*, vol. 27, no. 4, pp. 420–435, 2020.

H. Wang, C. Liu, Y. Zhao, and G. Gao, “Mitochondria regulation in ferroptosis,” *European Journal of Cell Biology*, vol. 99, no. 1, article 151058, 2020.

B. Proneth and M. Conrad, “Ferroptosis and necroinflammation, a yet poorly explored link,” *Cell Death & Differentiation*, vol. 26, no. 1, pp. 14–24, 2019.

B. Zhou, J. Liu, R. Kang, D. J. Klionsky, G. Kroemer, and D. Tang, “Ferroptosis is a type of autophagy-dependent cell death,” in *Seminars in cancer biology*, Elsevier, 2019.

M. P. Murphy, “Metabolic control of ferroptosis in cancer,” *Nature Cell Biology*, vol. 20, no. 10, pp. 1104–1105, 2018.

Q. Ma, “Role of nrf2 in oxidative stress and toxicity,” *Annual Review of Pharmacology and Toxicology*, vol. 53, no. 1, pp. 401–426, 2013.

M. Abdalkader, R. Lampinen, K. M. Kanninen, T. M. Malm, and J. R. Liddell, “Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration,” *Frontiers in Neuroscience*, vol. 12, p. 466, 2018.

A. S. Agyeman, R. Chaerkady, P. G. Shaw et al., “Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles,” *Breast Cancer Research and Treatment*, vol. 132, no. 1, pp. 175–187, 2012.
Oxidative Medicine and Cellular Longevity

[67] N. Harada, M. Kanayama, A. Maruyama et al., “Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages,” *Archives of Biochemistry and Biophysics*, vol. 508, no. 1, pp. 101–109, 2011.

[68] M. Dodson, R. Castro-Portuguez, and D. D. Zhang, “NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis,” *Redox Biology*, vol. 23, p. 101107, 2019.

[69] W. Cai, T. Yang, H. Liu et al., “Peroxisome proliferator-activated receptor y (PPARY): a master gatekeeper in CNS injury and repair,” *Progress in Neurobiology*, vol. 163, pp. 27–58, 2018.

[70] C. Lee, “Collaborative Power of Nrf2 and PPARγ Activators against Metabolic and Drug-Induced Oxidative Injury,” *Oxidative medicine and cellular longevity*, vol. 2017, Article ID 1378175, 14 pages, 2017.

[71] T. Itoh, L. Fairall, K. Amin et al., “Structural basis for the activation of PPARα by oxidized fatty acids,” *Nature Structural & Molecular Biology*, vol. 15, no. 9, pp. 924–931, 2008.

[72] X. Sun, Z. Ou, R. Chen et al., “Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells,” *Hepatology*, vol. 63, no. 1, pp. 173–184, 2016.

[73] C. Tonelli, I. C. Chio, and D. A. Tuveson, “Transcriptional regulation by Nrf2,” *Antioxidants & Redox Signaling*, vol. 29, no. 17, pp. 1727–1745, 2018.

[74] A. Houessinin, C. François, C. Sazuy et al., “Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib,” *Molecular Cancer*, vol. 15, no. 1, p. 38, 2016.

[75] S. Kabaria, D. C. Choi, A. D. Chaudhuri, M. R. Jain, H. Li, and E. Junn, “microRNA-7 activates Nrf2 pathway by targeting Keap1 expression,” *Free Radical Biology and Medicine*, vol. 89, pp. 548–556, 2015.

[76] G. Eades, M. Yang, Y. Yao, Y. Zhang, and Q. Zhou, “miR-200a regulates Nrf2 activation by targeting Keap1 mRNA in breast cancer cells,” *Journal of Biological Chemistry*, vol. 286, no. 47, pp. 40725–40733, 2011.

[77] M. Yang, Y. Yao, G. Eades, Y. Zhang, and Q. Zhou, “MiR-28 regulates Nrf2 expression through a Keap1-independent mechanism,” *Breast cancer research and treatment*, vol. 129, no. 3, pp. 983–991, 2011.

[78] J.-H. Kim, K.-S. Lee, D.-K. Lee et al., “Hypoxia-responsive microRNA-101 promotes angiogenesis via heme oxygenase-1/vascular endothelial growth factor axis by targeting cullin 3,” *Antioxidants & Redox Signaling*, vol. 21, no. 18, pp. 2469–2482, 2014.

[79] D. Xu, H. Zhu, C. Wang et al., “microRNA-455 targets cullin 3 to activate Nrf2 signaling and protect human osteoblasts from hydrogen peroxide,” *Oncotarget*, vol. 8, no. 35, article 59225, 2017.

[80] B. Singh, A. M. Ronghe, A. Chatterjee, N. K. Bhat, and H. K. Bhat, “MicroRNA-93 regulates Nrf2 expression and is associated with breast carcinogenesis,” *Carcinogenesis*, vol. 34, no. 5, pp. 1165–1172, 2013.

[81] C. Sangokoya, M. J. Telen, and J.-T. Chi, “microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease,” *Blood*, vol. 116, no. 20, pp. 4338–4348, 2010.

[82] M. Narasimhan, D. Patel, D. Vedpathak, M. Rathinam, G. Henderson, and L. Mahimainathan, “Identification of novel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal, SH-SYSY cells,” *PloS One*, vol. 7, no. 12, p. e51111, 2012.

[83] B. N. Chorley, M. R. Campbell, X. Wang et al., “Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha,” *Nucleic Acids Research*, vol. 40, no. 15, pp. 7416–7429, 2012.

[84] Y. Zhang, X. Tao, L. Yin et al., “Protective effects of dioscin against cisplatin-induced nephrotoxicity via the microRNA-34a/sirtuin 1 signalling pathway,” *British Journal of Pharmacology*, vol. 174, no. 15, pp. 2512–2527, 2017.

[85] G. Swaminathan, W. Zhu, and E. D. Plowey, “BECN1/Beclin 1 sorts cell-surface APP/amyloid β precursor protein for lysosomal degradation,” *Autophagy*, vol. 12, no. 12, pp. 2404–2419, 2016.

[86] X. Song, S. Zhu, P. Chen et al., “AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xc− Activity,” *Current Biology*, vol. 28, no. 15, pp. 2388–2399.e5, 2018.

[87] D. Tang and R. Kang, “Regulation and Function of Autophagy During Ferroptosis,” in *Ferroptosis in Health and Disease*, pp. 43–59, Springer, 2019.

[88] A. Kang, S. Zhu, H. J. Zeh, D. J. Klionsky, and D. Tang, “BECN1 is a new driver of ferroptosis,” *Autophagy*, vol. 14, no. 12, pp. 2173–2175, 2018.

[89] D. G. Hardie, B. E. Schaffer, and A. Brunet, “AMPK: an energy-sensing pathway with multiple inputs and outputs,” *Trends in Cell Biology*, vol. 26, no. 3, pp. 190–201, 2016.

[90] K. Shimada, R. Skouta, A. Kaplan et al., “Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis,” *Nature Chemical Biology*, vol. 12, no. 7, pp. 497–503, 2016.

[91] C. Li, X. Dong, W. Du et al., “LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis,” *Signal Transduction and Targeted Therapy*, vol. 5, no. 1, pp. 1–4, 2019.

[92] M. Gao, J. Yi, J. Zhu et al., “Role of mitochondria in ferroptosis,” *Molecular Cell*, vol. 73, no. 2, pp. 354–363.e3, 2019.

[93] S. Herzig and R. J. Shaw, “AMPK: guardian of metabolism and mitochondrial homeostasis,” *Nature Reviews Molecular Cell Biology*, vol. 19, no. 2, pp. 121–135, 2018.

[94] H. Lee, F. Zandkarimi, Y. Zhang et al., “Energy-stress-mediated AMPK activation inhibits ferroptosis,” *Nature Cell Biology*, vol. 22, no. 2, pp. 225–234, 2020.

[95] E. R. Kastenhuber and S. W. Lowe, “Putting p53 in context,” *Cell*, vol. 170, no. 6, pp. 1062–1078, 2017.

[96] F. Kruiswijk, C. F. Labuschagne, and K. H. Vousten, “p53 in survival, death and metabolic health: a lifeguard with a final destination for cancer?,” *Cell Proliferation*, vol. 53, no. 3, article e12761, 2020.

[97] R. Kang, G. Kroemer, and D. Tang, “The tumor suppressor protein p53 and the ferroptosis network,” *Free Radical Biology and Medicine*, vol. 133, pp. 162–168, 2019.

[98] L. Jiang, N. Kon, T. Li et al., “Ferroptosis as a p53-mediated activity during tumour suppression,” *Nature*, vol. 520, no. 7545, pp. 57–62, 2015.

[99] S.-J. Wang, Y. Li, J. Ou et al., “Acetylation is crucial for p53-mediated ferroptosis and tumor suppression,” *Cell Reports*, vol. 17, no. 2, pp. 366–373, 2016.
X. Meng, D. A. Franklin, J. Dong, and Y. Zhang, "MDM2–p53 pathway in hepatocellular carcinoma," Cancer Research, vol. 74, no. 24, pp. 7161–7167, 2014.

E. W. Gerner and F. L. Meyskens, "Polyamines and cancer: old molecules, new understanding," Nature Reviews Cancer, vol. 4, no. 10, pp. 781–792, 2004.

Y. Ou, S.-J. Wang, D. Li, B. Chu, and W. Gu, "Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses," Proceedings of the National Academy of Sciences, vol. 113, no. 44, pp. E6806–E6812, 2016.

B. J. Altman, Z. E. Stine, and C. V. Dang, "From Krebs to clinic: glutamine metabolism to cancer therapy," Nature Reviews Cancer, vol. 16, no. 10, pp. 619–634, 2016.

W. Hu, C. Zhang, R. Wu, Y. Sun, A. Levine, and Z. Feng, "Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function," Proceedings of the National Academy of Sciences, vol. 107, no. 16, pp. 7455–7460, 2010.

Y. Xie, S. Zhu, X. Song et al., "The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity," Cell Reports, vol. 20, no. 7, pp. 1692–1704, 2017.

E. M. Kim, C.-H. Jung, J. Kim, S.-G. Hwang, J. K. Park, and H.-D. Um, "The p53/p21 complex regulates cancer cell invasion and apoptosis by targeting Bcl-2 family proteins," Cancer Research, vol. 77, no. 11, pp. 3092–3100, 2017.

A. Tarangelo, L. Magtanong, K. T. Bieging-Rolett et al., "p53 suppresses metabolic stress-induced ferroptosis in cancer cells," Cell Reports, vol. 22, no. 3, pp. 569–575, 2018.

S. K. Anand, A. Sharma, N. Singh, and P. Kakkar, "Entrenching role of cell cycle checkpoints and autophagy for maintenance of genomic integrity," DNA Repair, vol. 86, article 102748, 2020.

W. Zhang, C. Gai, D. Ding, F. Wang, and W. Li, "Targeted p53 on small-molecules-induced ferroptosis in cancers," Frontiers in Oncology, vol. 8, p. 507, 2018.

P.-H. Chen, J. Wu, C.-K. C. Ding et al., "Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism," Cell Death & Differentiation, vol. 27, no. 3, pp. 1008–1022, 2020.